Role of interleukin-2 in patients with HIV infection

Drugs

Volumn 70, Issue 9, 2010, Pages 1115-1130

  Pett, Sarah L ^a,b   Kelleher, Anthony D ^a,b   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Aldesleukin, therapeutic use; HIV infections, treatment; Interleukin 2, therapeutic use

Indexed keywords

C REACTIVE PROTEIN; CD4 ANTIGEN; D DIMER; DIDANOSINE; HYDROXYUREA; OKT 3; PREDNISONE; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; FLU LIKE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOTHYROIDISM; INJECTION SITE REACTION; LYMPHOMA; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; RASH; REVIEW; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; HIV; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; RECOMBINANT PROTEINS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953094954     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10898620-000000000-00000     Document Type: Review

References (103)

1. Sodora DL, Silvestri G. Immune activation and AIDS pa-thogenesis. AIDS 2008; 22: 439-446
2. Pett SL, Kelleher AD. Cytokine therapies in HIV-1 infec-tion: present and future. Expert Rev Anti Infect Ther 2003; 1 (1): 83-96
3. Pallela Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860
4. Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34
5. The Antiretroviral (ART) Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368: 451-458
6. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741-749
7. Moore DM, Hogg RS, Chan K, et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006; 20: 371-377
8. The UK Collaborative HIV Cohort (CHIC) Study Steering Committee. HIV diagnosis at CD4 count above 500/uL and progression to below 350/uL without antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46: 275-278
9. Mocroft A, Phillips A, Gatell J, et al. Normalization of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370: 407-413
10. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/uL or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/uL or greater. J Acquir Immune Defic Syndr 2007; 45: 183-192
11. ART Collaboration Cohort. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299
12. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/uL on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007 Sep 1; 46 (1): 72-77
13. Kitahata MM, Gange SJ, Abraham AG, et al., NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009 Apr 30; 360 (18): 1815-1826
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. December 1, 2009 [online]. Available from URL: http://AIDSinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf [Accessed2010 Apr 20]
15. The D:A:D Study Group. Class of antiretroviral drugs and risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735
16. D:A:D Study Group. Use of nucleoside reverse tran-scriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-1426
17. The SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-24
18. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antire-troviral therapy. Science 1997; 278: 1295-1300
19. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viraemia. Science 1997; 278: 1291-1295
20. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998; 280 (5371): 1866-1867
21. Ho DD, Zhang L. HIV-1 rebound after anti-retroviral therapy. Nat Med 2000; 6 (7): 736-737
22. Mohri H, Perelson AS, Tung K, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001; 194 (9): 1277-1287
23. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371
24. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and non pathogenic lentiviral infections. Blood 2008; 112: 2826-2835
25. Pakker NG, Kroon ED, Roos MT, et al. Immune restora-tion does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 1999; 13 (2): 203-212
26. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17: 963-969
27. Rajesh G, Spritzler J, Chan E, et al. Effect of baseline-and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1 positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42: 426-434
28. Battegay M, Nuesch R, Hirschel B, et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6: 280-287
29. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44: 441-446
30. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296
31. Watson JD, Mochizuki DY, Gillis S. Molecular char-acterisation of interleukin-2. Fed Proc 1983; 42: 2747-2752
32. Rook AH, Hooks JJ, Quinnan GV, et al. Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. J Immunol 1985; 134: 1503-1507
33. Smith KA. Interleukin-2: inception, impact and implica-tions. Science 1988; 240: 1169-1177
34. Connors M, Kovacs JA, Krevat S, et al. HIV infection in-duces changes in CD4 T-cell phenotype and depletions within the CD4 T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3: 533-540
35. Shearer GM, Bernstein DC, Tung KS, et al. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immunodeficiency (AIDS). J Immunol 1986; 137: 2514-2521
36. Liegler TJ, Stites DP. HIV-1 gp120 and anti-gp120 in-duce reversible unresponsiveness in peripheral CD4 T-lymphocytes. J Acquir Immune Defic Syndr 1994; 7: 340-348
37. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor B. Proc Natl Acad Sci USA 1989; 86: 2336-2340 (Pubitemid 19102503)
38. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-1356
39. de Boer AW, Markowitz N, Lane HC, et al. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recom-binant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells. Clin Immunol 2003; 106: 188-196
40. Carr A, Emery S, Lloyd A, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multi-center study. J Infect Dis 1998; 178: 992-999
41. Levy Y, Capitant C, Houhou S, et al. Comparison of sub-cutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 1999; 353: 1923-1929
42. Davey RT, Chaitt DG, Albert JM, et al. A randomised trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179: 849-858
43. Davey RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy. JAMA 2000; 284: 183-189
44. Ruxrungtham K, Suwanagool S, Tavel JA, et al., Van-guard Study Group. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. AIDS 2000 Nov 10; 14 (16): 2509-2513
45. 3: CPCRA 059. J Acquir Immune Defic Syndr 2002; 29: 221-231
46. Davey RT, Chaitt RT, Piscitelli SC, et al. Subcutaneous ad-ministration of interleukin-2 in human immunodeficiency virus type-1 infected persons. J Infect Dis 1997; 175: 781-789
47. Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 2000; 182: 428-434
48. 3. J Infect Dis 2000 May; 181 (5): 1614-1621
49. Gougeon ML, Rouzioux C, Liberman I, et al., ANRS 048 Study Group. Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients. AIDS 2001 Sep 7; 15 (13): 1729-1731
50. Tambussi G, Ghezzi S, Nozza S, et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J Infect Dis 2001; 183: 1476-1484
51. Miller KD, Spooner K, Herpin BR, et al. Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4+ T-lymphocyte expansion. Clin Immunol 2001; 99 (1): 30-42
52. Tavel JA, Fosdick L. Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial. Control Clin Trials 2001; 22: 42-48
53. Levy Y, Durier C, Krzysiek R, et al., ANRS 079 Study Group. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003 Feb 14; 17 (3): 343-351
54. Farel CE, Chaitt DG, Hahn BK, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103: 3282-3286
55. Arduino RC, Nannini EC, Rodriguez-Barradas M, et al. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis 2004; 39: 115-122
56. Durier C, Capitant C, Lascaux A-S, et al. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). AIDS 2007; 21: 1887-1897
57. Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115 (8): 2139-2148
58. Read SW, Lempicki RA, Di Mascio M, et al. CD4+ T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis 2008; 198: 843-850
59. Sereti I, Sklar P, Ramchandani MS, et al. CD4+ T cell response to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis 2007; 196: 677-683
60. Sereti I, Martinez-Wilson H, Metcalf JA, et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood 2002; 100 (6): 2159-2167
61. Natarajan V, Lempicki RA, Sereti I, et al. Increased peri-pheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci USA 2002; 99 (16): 10712-10717
62. Sereti I, Anthony KB, Martinez-Wilson H, et al. IL-2-induced CD4 T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004; 104: 775-780
63. Levy Y, Gahery-Segard H, Durier C, et al., ANRS 093 Study Group. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005 Feb 18; 19 (3): 279-286
64. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5 (6): 651-655
65. Sereti I, Sklar P, Ramchandani MS, et al. CD4+ T cell re-sponses to interleukin-2 administration in HIV-Infected patients are directly related to the baseline levels of immune activation. J Infect Dis 2007; 196: 667-683
66. Proleukin®/Aldesleukin. Recombinant human interleukin-2/PRL002A for use in oncologic diseases. Investigator's brochure. Novartis edition number 1. Emeryville (CA): Novartis Vaccines and Diagnostics, Inc. 2007 Apr 30
67. Tavel JA, Sereti I, Walker RE, et al. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J Infect Dis 2003 Aug 15; 188 (4): 531-536
68. Auphan N, DiDanato JA, Rosette C, et al. Immuno-suppression by glucocorticoids: inhibition of NFkB activity through induction of IkB synthesis. Science 1995; 270: 286-290
69. Mitsuyasu R, Gelman R, Cherng DW, et al., for the AIDS Clinical Trials Group 328 Study Team. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial. AIDS Clinical Trials Group 328. Arch Intern Med 2007; 167 (6): 57-605
70. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996 Oct 1; 125 (7): 605-613
71. Hughes MD, Daniels MJ, Fischl MA, et al. CD4 cell count as a surrogate endpoint in HIV clinical trials: a metaanalysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12: 1823-1832
72. Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 1999; 13: 565-573
73. Abrams D, Levy Y, Losso MH, et al., INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009 Oct 15; 361 (16): 1548-1559
74. Katlama C, Carcelain G, Duvivier C, et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. AIDS 2002; 16 (15): 2027-2034
75. Table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004 [online]. Available from URL: http://rcc.tech-res. com/safetyandpharmacovigilance/[Accessed 2010 Apr 01]
76. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41: 1-19
77. Emery S, Abrams DI, Cooper DA, et al. The evaluation of subcutaneous proleukin® (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23: 198-220
78. Losso M, Abrams D, for the INSIGHT-ESPRIT Study Group. Effect of interleukin-2 on clinical outcomes in patients with a CD4+ cell count of 300/mm3: primary results of the ESPRIT study [abstract no. 90aLB]. 16th Conference on Retroviruses and Opportunistic Infections (CROI); 2009 Feb 8-11; Montreal (QC)
79. Porter BO, Shen J, Kovacs JA, et al. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS 2009 Sep 24; 23 (15): 2015-2019
80. Babiker AG, for the INSIGHT ESPRIT Study Group and the SILCAAT Scientific Committee. An analysis of pooled data from the ESPRIT and SILCAAT studies: findings by latest CD4+ count [abstract no. TUAB101]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009 Jul 19-22; Cape Town
81. Kuller LH, Tracy R, Belloso W, et al., for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008 Oct 21; 5 (10): e203
82. Stellbrink H-J, van Lunzen J, Westby M, et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002; 16: 1479-1487
83. Kulkosky J, Nunnari G, Otero M, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186: 1403-1411 (Pubitemid 35286107)
84. Youle M, Emery S, Fisher M, et al. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study [published erratum appears in PLoS Clin Trials 2007; 2(5): e23]. PLoS Clin Trials 2006 May; 1 (1): e3
85. Molina JM, Levy Y, Fournier I, et al., for Agence Natio-nale de Recherches sur le SIDA et les Hepatites Virales (ANRS) 119 Interstart Study Team. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis 2009; 200 (2): 206-215
86. Tavel JA, INSIGHT STALWART Study Group. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PLoS One 2010 Feb 23; 5 (2): e9334
87. Zoufaly A, Stellbrink HJ, Heiden MA, et al., for ClinSurv Study Group. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009 Jul 1; 200 (1): 79-87
88. Healey LM, Hahn BK, Rehm CA, et al. The effect of continuous versus pericycle antiretroviral therapy on IL-2 responsiveness. J Interferon Cytokine Res 2008 Jul; 28 (7): 455-462
89. Keh CE, Shen JM, Hahn B, et al. Interruption of antire-troviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. AIDS 2006 Feb 14; 20 (3): 361-369
90. Angus B, Lampe F, Tambussi G, et al. TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. AIDS 2008; 22 (6): 737-740
91. Porter BO, Anthony KB, Shen J, et al. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS 2009 Jan 14; 23 (2): 203-212
92. Davey RT, Pertel PE, Benson A, et al. Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antire-troviral therapy. J Interferon Cytokine Res 2008; 28: 89-100
93. Autran B, Carcelain G, Combadiere B, et al. Therapeutic vaccines for chronic infections. Science 2004; 305: 205-208
94. Leone A, Picker LJ, Sodora DL. IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. Curr HIV Res 2009 Jan; 7 (1): 83-90
95. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20: 405-413
96. Kilby JM, Bucy RP, Mildvan D, et al., Adult AIDS Clin-ical Trials Group A5024 Protocol Team. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006 Dec 15; 194 (12): 1672-1676
97. Smith KA, Andjelic S, Popmihajlov Z, et al. Immunother-apy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial. PLoS Clin Trials 2007 Jan 26; 2 (1): e5
98. Goujard C, Marcellin F, Hendel-Chavez H, et al., for the PRIMOVAC-ANRS 095 Study Group. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses 2007 Sep; 23 (9): 1105-1113
99. Johnston MI, Fauci AS. An HIV vaccine: evolving con-cepts. N Engl J Med 2007 May 17; 356 (20): 2073-2081
100. Cohen J. AIDS research: promising AIDS vaccine's failure leaves field reeling. Science 2007 Oct 5; 318 (5847): 28-29
101. Schooley R, Wang H, Spritzler J, et al., for the AIDS Clinical Trials Group. Therapeutic vaccination with a replication defective adenovirus type 5 HIV-1 gag vaccine in a prospective, double-blinded, placebo-controlled trial (ACTG 5197) [abstract no. 87]. 15th Conference on Ret-roviruses and Opportunistic Infections (CROI); 2008 Feb 3-6; Boston (MA)
102. Sereti I, Dunham RM, Spritzler J, et al. IL-7 administra-tion drives T cell cycle entry and expansion in HIV-1 infection. Blood 2009; 113 (25): 6304-6314
103. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell re-covery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009 Apr; 119 (4): 997-1007